My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 365

    1.

    Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].

    Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF; PROWESS Sepsis Study Group.

    Crit Care. 2004 Apr;8(2):R82-90. Epub 2004 Feb 10.PMID: 15025782 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.

    Lowry SF, Awad S, Ford H, Cheadle W, Williams MD, Qualy RL, McCollam JS, Bates BM, Fry DE; PROWESS Surgical Evaluation Committee.

    Surg Infect (Larchmt). 2004 Fall;5(3):261-8.PMID: 15684797 [PubMed - indexed for MEDLINE]Related articles

    3.

    Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae.

    Vail GM, Xie YJ, Haney DJ, Barnes CJ.

    Infection. 2009 Aug;37(4):358-64. Epub 2009 Jan 23.PMID: 19169631 [PubMed - indexed for MEDLINE]Related articles

    4.

    Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.

    Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR.

    Crit Care Med. 2005 Feb;33(2):341-8.PMID: 15699837 [PubMed - indexed for MEDLINE]Related articles

    5.

    Coagulation in sepsis: all bugs bite equally.

    Levi M, van der Poll T.

    Crit Care. 2004 Apr;8(2):99-100. Epub 2004 Feb 10.PMID: 15025767 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.

    Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT; PROWESS Sepsis Study Group.

    Thromb Haemost. 2003 Oct;90(4):642-53.PMID: 14515185 [PubMed - indexed for MEDLINE]Related articles

    7.

    Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

    Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

    Chest. 2004 Jun;125(6):2206-16.PMID: 15189943 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

    Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

    Crit Care Med. 2005 May;33(5):952-61.PMID: 15891319 [PubMed - indexed for MEDLINE]Related articles

    9.

    [Coagulation tests in septic surgical patients]

    Oberhofer D, Kucisec-Tepes N, Skok J, Vucić N, Cala K.

    Acta Med Croatica. 2004;58(5):389-94. Croatian. PMID: 15756805 [PubMed - indexed for MEDLINE]Related articles

    10.

    Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.

    Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL.

    Clin J Am Soc Nephrol. 2007 Jan;2(1):22-30. Epub 2006 Dec 13.PMID: 17699383 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.PMID: 18394162 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.PMID: 15640631 [PubMed - indexed for MEDLINE]Related articles

    13.

    Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients.

    Boldt J, Müller M, Heyn S, Welters I, Hempelmann G.

    Crit Care Med. 1996 Jun;24(6):940-6.PMID: 8681595 [PubMed - indexed for MEDLINE]Related articles

    14.

    Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.

    Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL.

    Shock. 2005 Jun;23(6):488-93.PMID: 15897799 [PubMed - indexed for MEDLINE]Related articles

    15.

    Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

    Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

    Pediatrics. 2004 Jan;113(1 Pt 1):7-17.PMID: 14702440 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

    Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA.

    Crit Care Med. 2001 Nov;29(11):2081-9.PMID: 11700399 [PubMed - indexed for MEDLINE]Related articles

    17.

    Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

    Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson DR, Derchak PA, Dhainaut JF.

    Crit Care Med. 2004 Dec;32(12):2385-91.PMID: 15599140 [PubMed - indexed for MEDLINE]Related articles

    18.

    Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

    Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR.

    Clin Infect Dis. 2003 Jul 1;37(1):50-8. Epub 2003 Jun 24.PMID: 12830408 [PubMed - indexed for MEDLINE]Related articles

    19.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

    20.

    Changes of the hemostatic network in critically ill patients--is there a difference between sepsis, trauma, and neurosurgery patients?

    Boldt J, Papsdorf M, Rothe A, Kumle B, Piper S.

    Crit Care Med. 2000 Feb;28(2):445-50.PMID: 10708181 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity